NCT05283226
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2022
Completion: Jun 30, 2025